Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 27.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,939 shares of the medical equipment provider's stock after buying an additional 5,825 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Hologic were worth $1,954,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the stock. Wolff Wiese Magana LLC purchased a new position in shares of Hologic in the third quarter valued at $25,000. General Partner Inc. bought a new stake in shares of Hologic in the fourth quarter valued at about $26,000. First Horizon Advisors Inc. raised its holdings in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 134 shares in the last quarter. Cromwell Holdings LLC raised its holdings in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 416 shares in the last quarter. Finally, Covestor Ltd raised its holdings in shares of Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider's stock valued at $56,000 after acquiring an additional 133 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.88% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms recently weighed in on HOLX. Evercore ISI decreased their price objective on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a report on Thursday, February 6th. Royal Bank of Canada decreased their price objective on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Raymond James reiterated an "outperform" rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, Leerink Partnrs lowered Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Ten equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Hologic presently has a consensus rating of "Moderate Buy" and an average price target of $85.77.

Hologic Stock Down 0.6 %

Shares of HOLX stock traded down $0.38 during trading hours on Friday, reaching $63.24. 2,320,041 shares of the company's stock were exchanged, compared to its average volume of 2,537,918. Hologic, Inc. has a 1 year low of $62.94 and a 1 year high of $84.67. The stock has a market cap of $14.19 billion, a PE ratio of 19.95, a PEG ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 3.03 and a debt-to-equity ratio of 0.52. The stock's fifty day moving average price is $71.04 and its two-hundred day moving average price is $77.26.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Research analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.